Genesis Drug Discovery & Development (GD³)
Madeline Farley, Ph.D., currently serves as the Chief Scientific Officer for the Biochemistry and Bioanalytical Division at Genesis Drug Discovery & Development (GD³) since July 2021, where responsibilities include leading services for preclinical drug discovery across various therapeutic areas. Previously, Madeline held roles as Managing Director and Senior Scientist, focusing on the development and execution of various assays and project management. Madeline's academic experience includes a postdoctoral researcher role at Baylor College of Medicine, leading research on retinal ganglion cell injury and signaling, and postdoctoral training in macromolecular structural biology at the University of Texas Medical School at Houston. Madeline obtained a Ph.D. in Cellular and Molecular Neuroscience from The University of Texas Health Science Center at Houston and a B.S. in Biochemistry with a Mathematics minor from Centenary College of Louisiana.
This person is not in the org chart
This person is not in any teams
Genesis Drug Discovery & Development (GD³)
Genesis Drug Discovery and Development (GD3), a member of the Genesis Biotechnology Group is a contract research organization focused on providing services to support preclinical drug development programs from discovery to candidate selection. Our diversified portfolio of services covers all the areas of preclinical drug discovery/development including Discovery Biology, Chemistry, DMPK/in-vivo pharmacology and Toxicology. The portfolio spans a wide range of therapeutic areas include oncology, ocular, inflammation, metabolic diseases, and microbiome.